CLINICAL_TRIALS
trial_result
· 2025-12-19
Clinical Trial Update: Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE) [Phase 2]
Summary
A Phase 2 trial of furmonertinib for EGFR-mutant non-small cell lung cancer with brain metastases has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Peking Union Medical College | Conditions: Furmonertinib, EGFR-mutation | Phase 2 | Status: COMPLETED